Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported better-than-expected Q2 earnings, with revenue of $15.56 billion and EPS of $6.31, primarily driven by a 46% volume increase in its GLP-1 drugs Mounjaro and Zepbound, the latter notably capturing over 60% of new weight-loss prescriptions. Despite this strong performance and market share gains against Novo Nordisk, the stock declined 13% due to disappointing late-stage trial results for its oral GLP-1 pill, orforglipron, which exhibited a high patient dropout rate, raising concerns about its pipeline's future despite current injectable market leadership.

Analysis

Eli Lilly (LLY) presented a bifurcated narrative in its second-quarter report, posting significantly better-than-expected financial results while simultaneously revealing a material setback in its drug pipeline. The company reported revenue of $15.56 billion and EPS of $6.31, comfortably beating Wall Street estimates of $14.69 billion and $5.56, respectively. This robust performance was driven by the exceptional commercial success of its GLP-1 franchise, where a 46% year-over-year increase in US sales volume for Mounjaro and Zepbound underscored its growing market dominance, despite an 8% price decline. Data confirms Lilly's competitive strength, with Zepbound prescriptions growing 225% YoY and capturing over 60% of new weight-loss prescriptions, effectively overtaking competitor Novo Nordisk's Wegovy. However, this strong operational momentum was overshadowed by disappointing late-stage trial results for its oral GLP-1 candidate, orforglipron, which reported a high 25% patient dropout rate. The immediate 13% decline in LLY's stock reflects investor concern that this pipeline asset, once seen as a key future growth driver, is now facing significant viability questions, creating a clear disconnect between the company's stellar current performance and its long-term growth outlook.

Key Decisions for Investors

• Investors must weigh the company's exceptional current commercial performance and market share dominance against the significant pipeline uncertainty created by the disappointing orforglipron trial results.
• It is critical to monitor for management's clarification on the anomalous orforglipron trial data, particularly the high placebo dropout rate, as this will determine the drug's path to potential FDA approval.
• The sharp stock decline may represent an entry point for investors confident in the durability of the injectable franchise, while more cautious investors should view the trial setback as a material risk to the long-term growth thesis.